PROVIDENCE – MindImmune Therapeutics Inc., a pharmaceutical startup, closed its second seed round of $500,000 on Monday. The round was led by a $250,000 investment from Slater Technology Fund, a publicly funded venture capital firm in Providence. MindImmune, based out of the University of Rhode Island, is developing drugs to target the immune system as…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.